ASH 2023 | The REMNANT study: will treating patients at MRD relapse improve survival outcomes?
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, introduces the REMNANT study (NCT04513639), which aims to investigate whether treating patients with multiple myeloma (MM) at measurable residual disease (MRD) relapse after first-line treatment will improve survival outcomes, specifically progression-free survival (PFS) and overall survival (OS). Patients enrolled in the study are treated with the Norwegian standard of care (SoC) first-line treatment of autologous stem cell transplantation (auto-SCT), induction and consolidation with bortezomib, lenalidomide, and dexamethasone (VRd) and lenalidomide maintenance. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
